Risk management in medical devices carries 2 identities. ISO 14971 defines a lifecycle process for identifying hazards, estimating and evaluating risk, controlling risk, and monit ...
Timothy Bassler, SVP of Quality Operations at PCI Pharma Services, presented "Driving Quality Culture to Manage Risk," using a ...
As part of PharmTech’s coverage of CPHI Milan, Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, ...
Sanofi and Cheplapharm have announced plans for a strategic partnership that would transfer 20 mature medicines and three ...
High-concentration biologics are pushing the limits of what can be formulated, filled, and delivered as a low-volume ...
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a ...
Keshav Bhutada, chief executive officer of Shilpa CDMO, said the company has long been recognized among existing partners for its capabilities with challenging molecules such as high-potency APIs ...
Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...
Christy Owings, vice president and general manager of the Americas business unit, Thermo Fisher Scientific, connected with ...
Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
Since July 2026, the European Union (EU) has shifted its focus from legislative reforms to practical applications, prioritizing supply-chain resilience, preventing medicine shortages, streamlining ...
Christy Owings, vice president and general manager of the Americas business unit at Thermo Fisher Scientific, discusses with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results